Breakpoints cover image

#68 – IDWeek 2022 Recap: Late Breaking Trials and Pipeline Antibacterials

Breakpoints

00:00

SCR 109 and C. Diff

SCR 109 was well tolerated through 24 weeks, and the most common side effects were mainly gastrointestinal. Ibiza is a small molecule guanazine analog that competitively inhibits the DNA pool 3C enzyme. It's different from SCR 109 in that it is a C. diff episode treatment product, not prevention for recurrence. The microbiome pearls at the end of these novel C. diff agents are always just so fascinating.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app